Article | July 29, 2020

Freeze-Drying COVID-19 Diagnostics: Formulation & Process Development And Lyophilizer Selection

By Dr Kevin Ward, Director of R&D, Biopharma Group

COVID 19 Coronavirus

Lyophilization may be considered a relatively gentle drying process, but there are still risks and pitfalls when applying it to biomolecular reagents in diagnostic tests that are different to the freeze-drying of general pharmaceuticals.

Reagents typically used in ELISA and PCR based diagnostic kits for diseases, such as COVID-19 tend to contain labile components, such as enzymes that need preserving for longevity in the supply chain or antibodies to test for a patients response to the virus, which can be challenging to stabilize for commercial use.

Recently, Dr Kevin Ward, Director of Research and Development at Biopharma Group, UK presented a webinar exploring various aspects of formulation and cycle development in the lyophilization of diagnostic reagents, including those required for COVID-19 testing that may be different to regular diagnostics. This article summarizes the webinar and includes a selection of questions from the Q&A session.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: